GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Senti Biosciences Inc (NAS:SNTI) » Definitions » Price-to-Free-Cash-Flow

Senti Biosciences (Senti Biosciences) Price-to-Free-Cash-Flow : N/A (As of Jun. 09, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Senti Biosciences Price-to-Free-Cash-Flow?

As of today (2024-06-09), Senti Biosciences's share price is $0.2806. Senti Biosciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.19. Hence, Senti Biosciences's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Senti Biosciences's Price-to-Free-Cash-Flow or its related term are showing as below:

SNTI's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.545
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Senti Biosciences's Free Cash Flow per Share for the three months ended in Mar. 2024 was $-0.26. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-1.19.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -35.80% per year.

During the past 4 years, Senti Biosciences's highest 3-Year average Free Cash Flow per Share Growth Rate was -35.80% per year. The lowest was -35.80% per year. And the median was -35.80% per year.


Senti Biosciences Price-to-Free-Cash-Flow Historical Data

The historical data trend for Senti Biosciences's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Senti Biosciences Price-to-Free-Cash-Flow Chart

Senti Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
- - - -

Senti Biosciences Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Senti Biosciences's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Senti Biosciences's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Senti Biosciences's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Senti Biosciences's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Senti Biosciences's Price-to-Free-Cash-Flow falls into.



Senti Biosciences Price-to-Free-Cash-Flow Calculation

Senti Biosciences's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.2806/-1.194
=N/A

Senti Biosciences's Share Price of today is $0.2806.
Senti Biosciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.19.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Senti Biosciences  (NAS:SNTI) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Senti Biosciences Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Senti Biosciences's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Senti Biosciences (Senti Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
2 Corporate Drive, First Floor, South San Francisco, CA, USA, 94080
Senti Biosciences Inc is a preclinical biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells.
Executives
Kanya Rajangam officer: Chief Medical & Devt. Officer C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Aktiengesellschaft Bayer 10 percent owner BAYERWERK, GEBAEUDE W11, KAISER-WILHELM-ALLEE, LEVERKUSEN 2M D-51368
Susan D Berland director C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Timothy K Lu director, officer: CEO and President SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
James J. Collins director C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Bayer World Investments B.v. 10 percent owner ENERGIEWEG 1, MIJDRECHT P7 3641
Deborah Knobelman officer: Chief Financial Officer C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Herberts Curt A. Iii officer: Chief Operating Officer 501 CANAL BLVD., POINT RICHMOND TECH CENTER, RICHMOND CA 94804
Brenda Cooperstone director C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Philip J Lee officer: Chief Technology Officer C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Edward T Mathers director C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Nea 15 Gp, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 15, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
New Enterprise Associates 15, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093